Apyx Medical Corp

Apyx Medical Corporation filed its Form 10-Q for the quarterly period ended September 30, 2026. The company reported an increase in sales for both the third quarter and the nine-month period compared to the previous year. However, the company continues to incur net losses, although the loss has narrowed year-over-year for both periods. Cash and cash equivalents decreased, and total equity also saw a reduction. The company also noted an increase in stock-based compensation expense.

Apyx Medical Corporation held its 2026 Annual Meeting of Stockholders on August 6, 2026. During the meeting, stockholders approved all proposals, including the election of five directors to the Board. They also ratified RSM US LLP as the independent registered public accounting firm for the year ending December 31, 2026. Additionally, stockholders approved a non-binding advisory resolution supporting the compensation of the company's named executive officers and adopted the 2026 Share Incentive Plan.

Apyx Medical reported Q2 2026 net sales of $13.88 million, an increase from $11.37 million in the prior year, with net loss attributable to stockholders improving to $(3.24) million from $(3.78) million. The company received expanded FDA 510(k) clearance for its AYON Body Contouring System™ to include power liposuction, commencing a limited commercial launch. Despite improved sales and narrowed losses, the company continues to incur recurring net losses and increased cash outflows from operations, raising liquidity concerns. Additionally, Apyx Medical is involved in ongoing product liability lawsuits and a new patent infringement lawsuit.

Apyx Medical Corporation reported a 22% increase in total revenue to $13.9 million for the second quarter ended June 30, 2026, primarily driven by 28% growth in its Surgical Aesthetics segment. The company's net loss attributable to stockholders narrowed to $3.2 million from $3.8 million in the prior year period. Apyx Medical also announced the successful limited launch of the power liposuction handpiece for its AYON platform and reaffirmed its full-year 2026 revenue guidance of $59.0 million to $60.0 million.

Apyx Medical reported strong second-quarter 2026 financial results, with total revenue increasing 22% to $13.9 million, primarily driven by a 28% growth in its Surgical Aesthetics segment. The company also significantly reduced its net loss to $3.2 million and narrowed its Adjusted EBITDA loss to $0.7 million. Operational highlights include expanded FDA 510(k) clearance for the AYON Body Contouring System and a successful limited launch of its power liposuction handpiece. Apyx Medical reaffirmed its full-year 2026 total revenue guidance of $59.0 million to $60.0 million.

Apyx Medical Corporation's Board of Directors reconstituted the membership and chairs of its standing committees, effective July 24, 2026. Lawrence J. Waldman will chair the Audit Committee, Minnie Baylor-Henry will chair the Governance and Nominating Committee and Regulatory Compliance Committee, and Wendy Levine will chair the Compensation Committee. Stavros Vizirgianakis will not serve on any committee following his appointment as Executive Chairman. All committee members are considered independent, and Mr. Waldman is an audit committee financial expert.

Apyx Medical Corporation announced its 2026 Annual Meeting of Stockholders will be held on August 6, 2026, at 9:00 a.m. EST in Uniondale, New York. Stockholders will vote on the election of five directors, the ratification of RSM US LLP as the independent auditor, a non-binding advisory resolution on executive compensation, and the approval of the 2026 Share Incentive Plan. The record date for determining stockholders entitled to vote is June 15, 2026. The Board unanimously recommends voting in favor of all proposals.

Apyx Medical Corporation announced the publication of new clinical data in Aesthetic Surgery Journal Open Forum. The study highlights a promising approach to improving cellulite and skin laxity using a combination treatment of Avéli for targeted subcision and Renuvion for skin laxity. Results at 180 days post-treatment showed up to 81.8% of patients improved in cellulite appearance, with objective 3D imaging demonstrating measurable reductions in dimple volume, surface area, and depth. Histological analysis also showed increases in collagen and elastin, indicating progressive tissue remodeling.

Apyx Medical announced the publication of new clinical data in Aesthetic Surgery Journal Open Forum, highlighting a promising approach to improving cellulite and skin laxity. The prospective investigator-initiated clinical study evaluated a combination treatment utilizing Avéli® for targeted subcision and Apyx's Renuvion® to reduce skin laxity. Results showed progressive improvement over time, with up to 81.8% of patients demonstrating improved cellulite appearance and increased levels of collagen and elastin observed in a subset through 180 days post-treatment.

Apyx Medical Corporation announced the publication of a new retrospective investigator-initiated study in Plastic and Reconstructive Surgery - Global Open. The study evaluated patient-reported outcomes following liposuction with and without helium plasma radiofrequency (Renuvion®). Results showed statistically significant improvements in patient satisfaction with abdominal appearance and excess skin, along with lower rates of abdominoplasty and surgical revisions, while maintaining comparable complication rates.